FIELD: medicine.
SUBSTANCE: claimed is medication including 2-[4-[2-(benzimidasol-2-ultio)ethyl]piperasin-1-yl]-N-[2,4-bismethyltio)-6-methyl-3-pyridyl]acetamide(further mentioned as compound 1), its pharmaceutically acceptable salt or its hydrate and pitavastatin and pharmacologically acceptable carrier, medication being intended for simultaneous introduction or separate introduction (versions); also claimed are versions of said medication application and pharmaceutical composition. Synergism of claimed compounds activity in reduction of plaque area size in aorta is shown. Processed with said composition plaques were most stabilised (i.e. 5.3% of plaque area contained macrophages, the remaining plaque area was occupied by collagen) in comparison with independent application of each of the components.
EFFECT: reduction of lipid-rich plaque, stabilisation of lipid-rich plaque and/or prevention of rupture of lipid-rich plaque in atherosclerotic affection.
13 cl, 2 dwg, 2 tbl
